Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice
| Autor: | Simona Puglisi, Rossella Paolini, Michael Mian, Renato Fanin, Francesco Rodeghiero, Giovanni Pizzolo, Monica Castelli, Sergio Cortelazzo, Ilaria Nichele, Gianpietro Semenzato, Paolo Vivaldi, Livio Trentin, Miriam Isola, Rosaria Sancetta, Stefano Volpetti, Achille Ambrosetti, Francesco Zaja, Carlo Visco, Cinzia Sissa |
|---|---|
| Přispěvatelé: | Zaja, Francesco, Mian, M, Volpetti, S, Visco, C, Sissa, C, Nichele, I, Castelli, M, Ambrosetti, A, Puglisi, S, Fanin, Renato, Cortelazzo, S, Pizzolo, G, Trentin, L, Rodeghiero, F, Paolini, R, Vivaldi, P, Sancetta, R, Isola, Miriam, Semenzato, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
Chronic lymphocytic leukemia Adult Aged Aged 80 and over Antibodies Monoclonal Murine-Derived Antineoplastic Agents Antineoplastic Agents Alkylating Antineoplastic Combined Chemotherapy Protocols Bendamustine Hydrochloride Female Follow-Up Studies Humans Leukemia Lymphocytic Chronic B-Cell Middle Aged Neoplasm Staging Neutropenia Nitrogen Mustard Compounds Prognosis Reproducibility of Results Retrospective Studies Rituximab Survival Analysis Gastroenterology Monoclonal 80 and over Chronic Leukemia Hematology Alkylating Lymphocytic Fludarabine medicine.drug Bendamustine Murine-Derived medicine.medical_specialty Antibodies Internal medicine medicine Progression-free survival Survival analysis business.industry B-Cell medicine.disease Surgery Concomitant business |
| Popis: | Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). However, the relationship between its activity with clinico-biological prognosticators has been addressed only in few studies. We retrospectively evaluated the efficacy of bendamustine, in a real-life contest, on 142 patients, median age 70 years, median number of previous regimens 2 (0–8, 13% previously untreated). Bendamustine was administered for a median number of 4 cycles, in 84% of cases with rituximab. Overall (ORR) and complete response (CRR) rates were 68 and 16.5%, respectively. Multivariate analysis demonstrated a relationship between ORR and number of prior treatments (OR 0.25, 95% CI 0.08–0.71; P = 0.009), del(17p) (OR 0.10, 95% CI 0.03–0.32; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|